Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | HTR1B | P28222 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15980865 | 1.00 | KDM4E (0.39) | KDM4EPOLBTDP1ADRB2ADRB1 | |
| SCHEMBL15980866 | 1.00 | KDM4E (0.39) | KDM4EPOLBTDP1ADRB2ADRB1 | |
| SCHEMBL25053660 | 1.00 | KDM4E (0.39) | KDM4EPOLBTDP1ADRB2ADRB1 | |
| SCHEMBL21106553 | 1.00 | KDM4E (0.39) | KDM4EPOLBTDP1ADRB2ADRB1 | |
| SCHEMBL21401381 | 0.90 | ALDH1A1 (0.40) | KDM4EPOLBTDP1ADRB2ADRB1 | |
| SCHEMBL18908756 | 0.88 | KDM4E (0.44) | KDM4EPOLBTDP1ADRB2ADRB1 | |
| SCHEMBL18908660 | 0.88 | KDM4E (0.44) | KDM4EPOLBTDP1ADRB2ADRB1 | |
| SCHEMBL22930120 | 0.88 | KDM4E (0.44) | KDM4EPOLBTDP1ADRB2ADRB1 | |
| SCHEMBL22837632 | 0.88 | KDM4E (0.44) | KDM4EPOLBTDP1ADRB2ADRB1 | |
| SCHEMBL10914222 | 0.88 | KDM4E (0.44) | KDM4EPOLBTDP1ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169660-A1 | CYCLIC AMINO-PYRAZINECARBOXAMIDE COMPOUNDS AND USES THEREOF | SILVERBACK THERAPEUTICS INC (US) | 2022-06-02 | — | — | US | disclosed |
| WO-2021102332-A1 | TGFBETAR2 INHIBITOR-LRRC15 ANTIBODY CONJUGATES AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. (US) | 2021-05-27 | — | — | WO | disclosed |
| US-20200121684-A1 | MODULATORS OF BTK PROTEOLYSIS AND METHODS OF USE | UNIV YALE (US) | 2020-04-23 | — | — | US | disclosed |
| US-20140243322-A1 | BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME | COFERON, INC. (US) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243322-A1 | BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME | BRDT, BRD2, BRD4 | KDM4E 1492/4885POLB 1099/4885TDP1 1842/4885 |
| US-20200121684-A1 | MODULATORS OF BTK PROTEOLYSIS AND METHODS OF USE | BTK, CBL, CRBN | KDM4E 1466/4885POLB 2875/4885TDP1 277/4885 |
| US-20220169660-A1 | CYCLIC AMINO-PYRAZINECARBOXAMIDE COMPOUNDS AND USES THEREOF | TGFBR2, ACVR2A, SMAD2 | KDM4E 2222/4885POLB 3264/4885TDP1 3584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.